Last reviewed · How we verify
Reconnect
Reconnect is a Biologic drug developed by Jill Hollway. It is currently in Phase 2 development.
Reconnect is a 4-arm randomized controlled trial testing the effectiveness of nostalgia-based messages and step-monitoring reminders in promoting walking among older adults. The trial also examines the impact of messages about water intake benefits on older adults.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Reconnect |
|---|---|
| Sponsor | Jill Hollway |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Hypnosis to Improve Well-beings of Critically Ill Patients and Prevent Post-intensive Care Syndrome (NA)
- Multisite Transspinal Stimulation for Augmenting Recovery in Spinal Cord Injury (NA)
- Postcards to Improve Remote Monitoring Connectivity Among Veterans With a Disconnected CIED (NA)
- Postcards to Improve Remote Monitoring Connectivity Among Veterans With a Disconnected Monitor (NA)
- Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome (PHASE3)
- Positive Psychology Intervention for Patients Post-bariatric Surgery and Their Partners (NA)
- REstoring CONsciousness With NEurostimulation of the Central Thalamus: The RECONNECT Study (EARLY_PHASE1)
- Long Term Effect of Brain Stimulation in PPA (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Reconnect CI brief — competitive landscape report
- Reconnect updates RSS · CI watch RSS
- Jill Hollway portfolio CI
Frequently asked questions about Reconnect
What is Reconnect?
Who makes Reconnect?
What development phase is Reconnect in?
Related
- Manufacturer: Jill Hollway — full pipeline
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing